Standout Papers

Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout 2005 2026 2012 2019 958
  1. Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout (2005)
    Michael A. Becker, H. Ralph Schumacher et al. New England Journal of Medicine
  2. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout (2018)
    William B. White, Kenneth G. Saag et al. New England Journal of Medicine
  3. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28‐week, phase III, randomized, double‐blind, parallel‐group trial (2008)
    H. Ralph Schumacher, Michael A. Becker et al. Arthritis Care & Research
  4. Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional Treatment (2011)
    John S. Sundy, Herbert S. B. Baraf et al. JAMA

Immediate Impact

4 by Nobel laureates 35 from Science/Nature 64 standout
Sub-graph 1 of 23

Citing Papers

Gout
2021 Standout
Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies
2021 Standout
21 intermediate papers

Works of Michael A. Becker being referenced

Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout
2014
Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional Treatment
2011 Standout
and 8 more

Author Peers

Author Last Decade Papers Cites
Michael A. Becker 3291 5344 3562 209 10.1k
Michael H. Weisman 2154 742 1472 338 21.6k
Karl Skorecki 4115 2207 1196 208 9.5k
Pietro Ghezzi 7716 1152 1272 404 24.6k
Ana Cristina Simões e Silva 2194 986 968 367 10.1k
Andrew Grey 2705 1422 1510 262 13.1k
Christian Jacobsen 4197 1044 812 144 10.7k
David B. Thomas 1735 1436 929 213 8.8k
Alex J. MacGregor 2215 240 2430 287 14.7k
John R. Bradley 2918 413 1143 149 7.8k
Eun‐Jung Rhee 1916 640 1341 294 9.4k

All Works

Loading papers...

Rankless by CCL
2026